Cód QR

Blockade of tumor cell-intrinsic PD-L1 signaling enhances AURKA-targeted therapy in triple negative breast cancer

Triple negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and mainly affects pre-menopausal and minority women. Because of the lack of ER, PR or HER2 expression in TNBC, there are limited options for tailored therapies. While TNBCs respond initially to standard of care chemother...

Cur síos iomlán

Sábháilte in:
Príomhchruthaitheoirí: Andrew Takchi, Minzhi Zhang, Mohammad Jalalirad, Roberto Leon Ferre, Royal Shrestha, Tufia Haddad, Jann Sarkaria, Ann Tuma, Jodi Carter, Hillman David, Karthik Giridhar, Liewei Wang, Carol Lange, Urban Lendahl, James Ingle, Matthew Goetz, Antonino Bonaventura D’Assoro
Formáid: Artigo
Teanga:Inglês
Foilsithe / Cruthaithe: Frontiers Media S.A. 2024-05-01
Sraith:Frontiers in Oncology
Ábhair:
triple negative breast cancer
immunotherapy
cancer cell plasticity
small molecule inhibitor
organ metastases
Rochtain ar líne:https://www.frontiersin.org/articles/10.3389/fonc.2024.1384277/full
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla